1ST Biotherapeutics (1STBIO) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Gyeonggi-do, South Korea. It discovers and develops novel small-molecule therapeutics for areas of significant unmet medical need, with programs spanning neurodegenerative disease, immuno-oncology, metabolic disease and rare/orphan disease, supported by a genomics-based target discovery capability and an R&D network of academic, hospital, CRO and investor partners. The company sells no software product and operates no developer program: its public web presence is an eight-page corporate and investor site with no API, SDK, developer portal or machine-readable contract of any kind.
1ST Biotherapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Drug Discovery, and Life Sciences.
1ST Biotherapeutics’ developer surface includes support and 4 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
aid: 1stbiotherapeutics
name: 1ST Biotherapeutics
description: '1ST Biotherapeutics (1STBIO) is a clinical-stage biopharmaceutical company founded in 2016 and headquartered
in Gyeonggi-do, South Korea. It discovers and develops novel small-molecule therapeutics for areas of significant unmet
medical need, with programs spanning neurodegenerative disease, immuno-oncology, metabolic disease and rare/orphan disease,
supported by a genomics-based target discovery capability and an R&D network of academic, hospital, CRO and investor partners.
The company sells no software product and operates no developer program: its public web presence is an eight-page corporate
and investor site with no API, SDK, developer portal or machine-readable contract of any kind.'
image: https://www.1stbio.com/android-chrome-192x192.png
url: https://raw.githubusercontent.com/api-evangelist/1stbiotherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-harvest:
source: secondary-market
url: https://equityzen.com/company/1stbiotherapeutics
status: 200
note: Secondary-market venue listing the company was surfaced from. Recorded as harvest provenance only — it is NOT the
company's Website, which is https://www.1stbio.com/.
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-09-05'
modified: '2026-09-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Drug Discovery
- Life Sciences
- Healthcare
- Oncology
- Neurodegenerative Disease
- Rare Disease
- South Korea
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/1stbiotherapeutics-domain-security.yml
- type: LLMsTxt
url: llms/1stbiotherapeutics-llms.txt
- type: Website
url: https://www.1stbio.com/
- type: PrivacyPolicy
url: https://www.1stbio.com/privacy-policy/
- type: Support
url: https://www.1stbio.com/contact-us/
x-enrichment:
date: '2026-09-05'
status: minimal
artifacts_added: 3
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 1ST Biotherapeutics is a clinical-stage drug-discovery company whose entire public web presence is an eight-page
WordPress marketing and investor site; no api./developer./docs./ dev./portal. subdomain of 1stbio.com resolves in DNS,
every /.well-known/ discovery path 404s, and the only machine-readable endpoint on the domain is the stock WordPress REST
API discovery document at /wp-json (namespaces wp/v2, oembed/1.0, yoast/v1, gravityforms/v2) — default CMS infrastructure,
not a product API the company designed or supports.
evidence:
- url: https://www.1stbio.com/
status: 200
- url: https://www.1stbio.com/openapi.json
status: 404
- url: https://www.1stbio.com/.well-known/agent-card.json
status: 404
- url: https://www.1stbio.com/llms.txt
status: 404
- url: https://www.1stbio.com/wp-json
status: 200
checked: '2026-09-05'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.
Kin Score
How this is scored →